INVO Bioscience Management

Management criteria checks 4/4

INVO Bioscience's CEO is Steve Shum, appointed in Oct 2019, has a tenure of 4.58 years. total yearly compensation is $232.68K, comprised of 86.8% salary and 13.2% bonuses, including company stock and options. directly owns 0.24% of the company’s shares, worth $6.02K. The average tenure of the management team and the board of directors is 4 years and 3.7 years respectively.

Key information

Steve Shum

Chief executive officer

US$232.7k

Total compensation

CEO salary percentage	86.8%
CEO tenure	4.6yrs
CEO ownership	0.2%
Management average tenure	4yrs
Board average tenure	3.7yrs

Recent management updates

Recent updates

INVO Bioscience launches INVOcell in Malaysia

Aug 25

INVO BioScience GAAP EPS of -$0.23 beats by $0.01, revenue of $0.14M misses by $0.19M

Aug 15

INVO Bioscience names Andrea Goren as chief financial officer

Jun 15

CEO Compensation Analysis

How has Steve Shum's remuneration changed compared to INVO Bioscience's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-US$7m
Dec 31 2023	US$233k	US$202k	-US$8m
Sep 30 2023	n/a	n/a	-US$9m
Jun 30 2023	n/a	n/a	-US$10m
Mar 31 2023	n/a	n/a	-US$11m
Dec 31 2022	US$502k	US$260k	-US$11m
Sep 30 2022	n/a	n/a	-US$8m
Jun 30 2022	n/a	n/a	-US$8m
Mar 31 2022	n/a	n/a	-US$7m
Dec 31 2021	US$298k	US$260k	-US$7m
Sep 30 2021	n/a	n/a	-US$10m
Jun 30 2021	n/a	n/a	-US$10m
Mar 31 2021	n/a	n/a	-US$9m
Dec 31 2020	US$422k	US$260k	-US$8m
Sep 30 2020	n/a	n/a	-US$5m
Jun 30 2020	n/a	n/a	-US$4m
Mar 31 2020	n/a	n/a	-US$3m
Dec 31 2019	US$2m	US$73k	-US$2m
Sep 30 2019	n/a	n/a	-US$2m
Jun 30 2019	n/a	n/a	-US$2m
Mar 31 2019	n/a	n/a	-US$3m
Dec 31 2018	US$179k	n/a	-US$3m
Sep 30 2018	n/a	n/a	-US$3m
Jun 30 2018	n/a	n/a	-US$2m
Mar 31 2018	n/a	n/a	-US$632k
Dec 31 2017	US$23k	n/a	-US$702k

Compensation vs Market: Steve's total compensation ($USD232.68K) is below average for companies of similar size in the US market ($USD661.47K).

Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.

CEO

Steve Shum (52 yo)

4.6yrs

Tenure

US$232,675

Compensation

Mr. Steven M. Shum, also known as Steve, has been an Independent Director at Expion360 Inc. since April 05, 2022. Mr. Shum has been the Chief Executive Officer of INVO Bioscience, Inc. since October 10, 20...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Steven Shum	CEO & Director	4.6yrs	US$232.68k	0.24% $ 6.0k
Andrea Goren	Chief Financial Officer	2.9yrs	US$198.70k	0.28% $ 7.1k
Michael Campbell	COO & VP of Business Development	5.3yrs	US$275.00k	0.14% $ 3.5k
Bojan Mitrovic	Director of Sales US	2.3yrs	no data	no data
Robert Bowdring	Treasurer & Secretary	7.7yrs	no data	no data
Terah Krigsvold	Controller	3.4yrs	no data	no data

4.0yrs

Average Tenure

60.5yo

Average Age

Experienced Management: INVO's management team is considered experienced (4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Steven Shum	CEO & Director	6.6yrs	US$232.68k	0.24% $ 6.0k
Trent Davis	Independent Director	4.4yrs	US$67.32k	0.061% $ 1.5k
Barbara Ryan	Independent Director	3.7yrs	US$74.20k	0.058% $ 1.4k
Matthew Szot	Independent Director	3.7yrs	US$74.20k	0.071% $ 1.8k
Rebecca Messina	Independent Director	3.1yrs	US$66.07k	0.042% $ 1.1k
Tony Anderson	Scientific Advisory Board Member	no data	no data	no data
Amber Cooper	Scientific Advisory Board Member	no data	no data	no data
Francisco Arredondo	Scientific Advisory Board Member	no data	no data	no data
Karen Hammond	Scientific Advisory Board Member	no data	no data	no data

3.7yrs

Average Tenure

52yo

Average Age

Experienced Board: INVO's board of directors are considered experienced (3.7 years average tenure).

INVO Bioscience Management

Management criteria checks 4/4

Key information

Recent management updates

High number of new directors

High number of new directors

INVO Bioscience, Inc., Annual General Meeting, Oct 12, 2022

INVO Bioscience, Inc., Annual General Meeting, Dec 28, 2020

INVO Biosciences Announces the Appointment of Jeffrey J. Segal as a Director of the Company

INVO Bioscience, Inc Announces Board Changes

Recent updates

INVO Bioscience, Inc. Receives Non-Compliance Letter related to Nasdaq Listing Rule 5550(b)(1)

INVO Bioscience, Inc. announced delayed annual 10-K filing

Forecast to breakeven in 2026

NAYA Biosciences Inc. Announces Publication of New Data for its CD38-targeted Flex-NK Bispecific Antibody in the American Society of Hematology's Blood Journal

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

NAYA Biosciences entered into an agreement to acquire INVO Bioscience, Inc. (NasdaqCM:INVO) in a reverse merger transaction for $9.8 million.

NAYA Biosciences entered into an agreement to acquire INVO Bioscience, Inc. (NasdaqCM:INVO) in a reverse merger transaction for $9.8 million.

Consensus revenue estimates decrease by 24%, EPS upgraded

New major risk - Negative shareholders equity

New major risk - Shareholder dilution

INVO Bioscience, Inc. to Report Q2, 2023 Results on Aug 14, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

INVO Bioscience, Inc. has completed a Composite Units Offering in the amount of $4.503 million.

INVO Bioscience, Inc. has completed a Composite Units Offering in the amount of $4.503 million.

INVO Bioscience Announces Reverse Stock Split to Bring the Company into Compliance with Nasdaq's $1.00 Per Share Minimum Bid Price Requirement for Continued Listing

INVO Bioscience, Inc. Receives 510(K) FDA Clearance for Expanded Use of the Invocell Device

INVO Bioscience Receives Notice by the Listing Qualifications Department of the Nasdaq Regarding Listing Rule 5550(b)(1)

No longer forecast to breakeven

INVO Bioscience, Inc. to Report Q1, 2023 Results on May 15, 2023

No longer forecast to breakeven

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

INVO Bioscience Receives A Letter from Nasdaq to Grant the Company an Extension of Time to Regain Compliance with Nasdaq Listing Rule 5550(b) Until May 22, 2023

INVO Bioscience Receives a Letter from the Staff of The Nasdaq Stock Market LLC

INVO Bioscience, Inc. announced that it expects to receive $0.275 million in funding

Forecast to breakeven in 2025

INVO Bioscience, Inc. Announces First Baby Born in Malaysia Utilizing Innovative INVOcell Assisted Reproductive Technology

Consensus EPS estimates fall by 31%

INVO Bioscience Receives Non Compliance Notice from Nasdaq

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$2.00

High number of new directors

Price target decreased to US$2.00

High number of new directors

INVO Bioscience, Inc. to Report Q3, 2022 Results on Nov 14, 2022

INVO Bioscience, Inc., Annual General Meeting, Oct 12, 2022

INVO Bioscience launches INVOcell in Malaysia

INVO BioScience GAAP EPS of -$0.23 beats by $0.01, revenue of $0.14M misses by $0.19M

INVO Bioscience, Inc. to Report Q2, 2022 Results on Aug 15, 2022

INVO Bioscience, Inc. to Report Q1, 2022 Results on May 16, 2022

INVO Bioscience Obtains Regulatory Approval to Commercialize INVOcell In Thailand

INVO Bioscience, Inc. (NasdaqCM:INVO) completed the acquisition of Effortless IVF Canada, Inc.

INVO Bioscience, Inc. (NasdaqCM:INVO) entered into a share transfer agreement to acquire Effortless IVF Canada, Inc., from Lyle Oberg, Jason Broome, Richard Ross and Seang Lin Tan for CAD 0.46 million.

INVO Bioscience names Andrea Goren as chief financial officer

INVO Bioscience Obtains Regulatory Approval to Import INVOcell Into Mexico

INVO Bioscience Advances Commercialization into the European Fertility Market with Initial Orders of INVOcell (IVC) in Spain

INVO Bioscience Expands Distribution of INVOcell Into the Pakistan Infertility Market with Galaxy Pharma Ltd

INVO Bioscience, Inc. and idsMED Group Enter Distribution Agreement for Malaysia

INVO Bioscience, Inc., Annual General Meeting, Dec 28, 2020

Invo Bioscience's Common Stock Deleted from Other OTC

INVO Biosciences Announces the Appointment of Jeffrey J. Segal as a Director of the Company

INVO Bioscience, Inc. Establishes Joint Venture to Operate INVOcell Fertility Clinics in Mexico

INVO Bioscience, Inc Announces Board Changes

INVO Bioscience, Inc. announced that it has received $3.49484 million in funding

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age